CoChat

Inclisiran: A Novel Agent for Lowering Apolipoprotein B–containing Lipoproteins

Warden, Bruce A., Duell, Paul Barton · 2021 · Journal of Cardiovascular Pharmacology

The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.

Abstract

Hypercholesterolemia is a leading cause of cardiovascular morbidity and mortality. Accordingly, efforts to lower apolipoprotein B–containing lipoproteins in plasma are the centerpiece of strategies for cardiovascular prevention and treatment in primary and secondary management. Despite the importance of this endeavor, many patients do not achieve appropriate low-density lipoprotein cholesterol (LDL-C) and non–high-density lipoprotein cholesterol (non-HDL-C) goals, even among those who have experienced atherosclerotic cardiovascular disease. The development of new LDL-C-lowering medications with alternative mechanisms of action will facilitate improved goal achievement in high-risk patients. Inclisiran is a novel small interfering RNA–based drug that is experimental in the United States and approved for clinical use in the European Union. It lowers LDL-C and other apolipoprotein B–containing lipoproteins by reducing production of proprotein convertase subtilisin/kexin Type 9 (PCSK9), a protein that normally contributes to LDL-receptor degradation, thereby increasing LDL-receptor density and recycling in hepatocytes. Although the lipid-lowering efficacy of inclisiran is comparable with results achieved with PCSK9-blocking monoclonal antibodies (alirocumab and evolocumab), there are several important differences between the 2 drug classes. First, inclisiran reduces levels of PCSK9 both intracellularly and extracellularly by blocking translation of and degrading PCSK9 messenger RNA. Second, the long biological half-life of inclisiran produces sustained LDL-C lowering with twice yearly dosing. Third, although PCSK9-blocking monoclonal antibodies drugs are proven to reduce atherosclerotic cardiovascular disease events, clinical outcomes trials with inclisiran are still in progress. In this article, we review the clinical development of inclisiran, its mechanism of action, lipid-lowering efficacy, safety and tolerability, and potential clinical role of this promising new agent.

Overview

Integrity signals

Registry

Crossref · 10.1097/fjc.0000000000001053

Cites

95 of 95 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 95 references

Research works printed but not linked: 2

  1. Wright, 2020, For the ORION phase III investigators abstract 16427: efficacy and safety of inclisiran according to age: a pooled analysis of phase III studies (ORION 9, 10 and 11), Circulation, 142, A16427
  2. Wright, 2020, For the ORION phase III investigators abstract 16311: efficacy and safety of inclisiran according to sex: a pooled analysis of the ORION 9, 10 and 11 trials, Circulation, 142, A16311

Cited by

See all 62

Metadata

Authors
Warden, B. A., & Duell, P. B.
Affiliations
Oregon Health & Science University (US)
Corresponding author
  • Warden, Bruce A.
  • Duell, Paul Barton
Venue
Journal of Cardiovascular Pharmacology
Published
2021-08
Volume
78
Issue
2
Pages
e157-e174
ISSN
0160-2446 (ISSN-L)
OpenAlex
W3160485478
Cited by
62
References
95
Citations by year
2026: 5 · 2025: 7 · 2024: 11 · 2023: 21 · 2022: 15 · 2021: 3
FWCI
3.07
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Cardiovascular Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
inclisiran, PCSK9, siRNA, apolipoprotein B-containing lipoproteins, LDL cholesterol lowering, hypercholesterolemia, PCSK9 inhibitors, LDL receptor, atherosclerotic cardiovascular disease, lipid-lowering therapy, drug safety and tolerability
MeSH terms
Proprotein Convertase 9, PCSK9 Inhibitors, Animals, Humans, Hypercholesterolemia, Cholesterol, LDL, Biomarkers, Down-Regulation, Treatment Outcome, RNA Interference, RNA, Small Interfering, Apolipoprotein B-100

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inclisiran: A Novel Agent for Lowering Apolipoprotein B–containing Lipoproteins. https://app.cochat.ai/papers/10.1097/fjc.0000000000001053
The paper
Warden, B. A., & Duell, P. B. (2021). Inclisiran: A Novel Agent for Lowering Apolipoprotein B–containing Lipoproteins. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/fjc.0000000000001053

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.